Skip to main content
Biophysical Journal logoLink to Biophysical Journal
. 2022 Jun 6;121(13):2490–2502. doi: 10.1016/j.bpj.2022.06.006

Understanding the molecular mechanism of endothelin ETA receptor selecting isopeptides endothelin-1 and -3

Lingyun Wang 1,, Lingling Wang 2, Feng Yan 3,4,∗∗
PMCID: PMC9300638  PMID: 35660104

Abstract

Endothelin-1 and -3 (ET1 and ET3) are potent vasoconstricting isopeptides that are involved in the pathophysiology of various diseases, such as cardiovascular and renal diseases. The two ETs exert their effects by binding to two G-protein-coupled receptors (GPCRs), the endothelin ETA receptor (ETAR) and the endothelin ETB receptor (ETBR). ETAR and ETBR reveal different preferences in the recognition of the two ETs: The binding affinity of ETAR with ET1 is much higher than that with ET3, while the binding affinities of ETBR with the two ETs are similar. Recently, the structures of ETBR with ET1 and ET3 were determined. These crystal structures provide detailed descriptions of how ETBR interacts with ET1 and ET3. However, the knowledge of how ETAR recognizes the two isopeptides is still lacking. Based on the structure of ETBR in complex with ET1, the structures of ETAR with ET1 and ET3 were modeled. Then, molecular dynamics simulations were performed to study how ETAR discriminates the two ETs. Simulation results demonstrate that ET1 has greater binding free energy with ETAR than ET3, which is in agreement with the binding affinity data of ETAR. By interaction energy analysis, the key residues of ETAR that discriminate between ET1 and ET3 are identified. Structural and dynamical analyses indicate that, compared with ET3, ET1 is more stable in binding with ETAR. Furthermore, the orientation change of W319 in the conserved CWxP motif that plays an important role in the signaling function of GPCRs was observed. Through the orientation change of this residue, the difference in the orthosteric pocket volume resulting from the binding of ET1 and ET3 on the extracellular side of ETAR leads to a conformational difference of TM6 on the intracellular side of ETAR. This study elucidates the molecular mechanism of how ETAR selects the isopeptides ET1 and ET3.

Graphical abstract

graphic file with name fx1.jpg

Significance

To date, how ETAR discriminates ET1 from ET3 is still unknown, since no crystal, cryo-EM, or NMR structure of ETAR is available. In this study, the structures of ETAR in complex with ET1 and ET3 were set up by homology modeling. Through molecular simulations, we found that ET1 shows higher structural and dynamical stabilities compared with ET3, and has a preferable binding free energy with ETAR. The key residues that play important roles in recognizing ET1 and ET3 have also been identified through interaction energy analysis. Our results provide insights into the molecular mechanism of how ETAR discriminates ET1 from ET3, which may help to design novel endothelin receptor antagonists to treat the cardiovascular and renal diseases caused by endothelins.

Introduction

Endothelins (ETs) are a family of potent vasoconstricting isopeptides that have been implicated in the pathophysiology of cardiovascular diseases, pulmonary diseases, cancers, and renal diseases (1,2). To date, three isoforms of ETs have been found. All of them contain 21 amino acids in their mature and active forms (3). Endothelin-1 (ET1) is the most prevalent isoform, which is widely expressed in various cells, such as endothelial cells, vascular smooth muscle cells, and epithelial cells (4,5). ET1 is currently identified as the most potent endogenous vasoconstrictor. It can produce extremely powerful contraction of human arteries and veins, and the effect of the contraction is long-lasting and difficult to wash out (4). While ET2 is mainly expressed in the gastrointestinal tract (6), ET3 is detected in plasma, the heart, brain, and other tissues (4,7). Besides its vasoconstrictor role, ET3 can mediate the release of vasodilator molecules, such as nitric oxide, and induce a relatively more potent vasodilator action than the other two ETs (8).

ETs exert their effects by binding to two G-protein-coupled receptors (GPCRs), the endothelin ETA receptor (ETAR) and the endothelin ETB receptor (ETBR) (9). ETAR is found in vascular smooth muscle cells and many human tissues including the heart, lung, and kidney, whereas ETBR is located in vascular endothelial cells and has a high expression level in the brain (4). The two receptors are involved in a vast array of physiological processes, such as vasoconstriction/vasodilatation, bronchoconstriction, and cell proliferation (10). ETAR and ETBR reveal different preferences in the recognition of the three ET isopeptides: ETAR binds ET1 and ET2 with similar affinities, but ET3 with 100-fold lower affinity (ET1 ≈ ET2 >> ET3) (11). In contrast, ETBR recognizes all the three isoforms with similar affinities (ET1 ≈ ET2 ≈ ET3) (12).

Recently, the structures of the human ETBR in complex with ET1 and ET3 have been determined through x-ray crystallography (13,14). The structural data show that the ETBR adopts a typical GPCR architecture that contains seven transmembrane helices (TM1-7) and an intracellular helix (helix 8) in the C-terminal region. ET1 and ET3 fit in the orthosteric pocket of ETBR, which is covered by a conserved β-hairpin motif in the extracellular loop 2 (ECL2). Both ETs adopt a bicyclic structure with two intrachain disulfide bond pairs (C1-C15 and C3-C11), and the two ETs can be divided into three regions (Fig. 1 A): the N-terminal region (residues 1–7), the α-helical region (residues 8–17), and the C-terminal region (residues 18–21), which deeply penetrates into the pocket of the receptor. In addition to determining the crystal structure of ETBR with ET3, Shihoya et al. also investigated the binding affinities of ET1 and ET3 to ETAR and ETBR through TGF-α shedding and β-arrestin recruitment assays (14). In both assays, the binding affinities of ET3 to ETBR are similar to those of ET1 to ETBR (the EC50 values for ET1 and ET3 are 0.11 and 0.13 nM, respectively, in the TGF-α shedding assay; and the EC50 values for ET1 and ET3 are 2.7 and 3.3 nM, respectively, in the β-arrestin recruitment assay), while the binding affinities of ET1 to ETAR was about fivefold lower than those of ET3 to ETAR (the EC50 values for ET1 and ET3 are 0.13 and 0.65 nM, respectively, in TGF-α shedding assay; and the EC50 values for ET1 and ET3 are 2.3 and 10.8 nM, respectively, in the β-arrestin recruitment assay). These data further confirm the notion that ETAR has a higher selectivity of ET1 than ET3.

Figure 1.

Figure 1

Initial simulation structure and structural deviations. (A) Endothelin-1 and -3 (ET1 and ET3) are modeled in the orthosteric pocket of endothelin type A receptor (ETAR). The simulation systems of ETAR with ET1 and ET3 are denoted as ETAR-ET1 (I) and ETAR-ET3 (II), respectively. The three regions of ET1/3, i.e., the N-terminal, α-helical, and C-terminal regions, are shown in cyan, orange, and purple, respectively. The black dashed lines indicate the surfaces of membrane. (B) Root mean-square deviations (RMSDs) for Cα atoms of ETAR (black lines) and for that of ET1 or ET3 (red lines) as a function of simulation time. Three 1,000 ns molecular dynamics simulations were performed for each system. (C) Comparison of the binding of ET1 and ET3 in the orthosteric pocket of ETAR. Representative structures of ETAR-ET1 and ETAR-ET3 were used for comparison. The residues different between ET1 and ET3 are labeled in cyan and blue, respectively. To see this figure in color, go online.

The crystal structures provide detailed descriptions of how ETBR interacts with ET1 and ET3. However, the knowledge of how ETAR recognizes the two isopeptides is still lacking since the structure of ETAR is not available to date. To this end, the structural models of ETAR in complex with ET1 and ET3 were built based on the structure of ETBR with ET1. Then, three 1,000 ns molecular dynamics simulations were performed for each model. The simulation results demonstrate that ETAR has a greater binding free energy with ET1 than ET3, which is consistent with the binding affinity data of ETAR. By interaction energy analysis, the key residues of ETAR that discriminate between ET1 and ET3 are identified. Structural and dynamical analyses indicate that, compared with ET3, ET1 is more stable in binding with ETAR. Furthermore, the volume of the orthosteric pocket is increased in the binding of ET3 compared with that in the binding of ET1. This study elucidates the molecular mechanism of how ETAR discriminates the isopeptides ET1 and ET3, which may help in designing novel ET receptor antagonists to treat cardiovascular and renal diseases.

Materials and methods

Homology modeling

The structural models of ETAR in complex with ET1 and ET3 were built using the software MODELLER 9.13 (15). The crystal structure of ETBR in complex with ET1 (PDB: 5GLH) (13) was used as a template for the modeling. Before modeling, the structure of bacteriophage T4 lysozyme (used to facilitate crystallization) was removed from the template. The sequence of ETAR was aligned with that of ETBR based on the work of Shihoya et al. (13). Totally, 100 homology models were generated by MODELLER, and the modeled structure with the lowest DOPE energy was chosen as the best model. The disulfide bonds (C69-C340 and C159-C239 in ETAR, and C1-C15 and C3-C11 in ET1) were retained in the modeled structures. The residues of ETAR corresponding to those missing in the template of ETBR were added by MODELLER. The protonation states of the titratable residues were determined using the H++ program (16). Histidine was protonated at the epsilon nitrogen, and all the other titratable residues were assigned the protonation states corresponding to their default values at neutral pH. The modeled structure of ETAR includes amino acids 67–384, and contains the secondary structures of TM1-7, ICL1-3, ECL1-3, and helix 8 (Figs. 1 A and S1). To validate our model, the quality of the modeled structures was evaluated using the QMEANDisCo global score (17). The score value is 0.60 ± 0.05, indicating that our models are reliable.

The amino acids of ET3 that are different from ET1 (Fig. 1 A) were substituted using the mutagenesis function of CHARMMI-GUI (18). The two simulation systems of ETAR in complex with ET1 and ET3 are denoted ETAR-ET1 and ETAR-ET3, respectively. The membrane environment was modeled by a palmitoyl-oleoyl-phosphatidyl-choline bilayer composed of 127 lipid molecules using the CHARMMI-GUI membrane builder (18). Then TIP3P water molecules were added to the two sides of the lipid bilayer (Fig. S1), which resulted in a simulation box of 74 × 74 × 130 Å along the x, y, and z directions, respectively. The parameters of the FF99SB force field (19) were assigned to the protein, ions, and water molecules, while the FFlipid14 force field (20) was used for the palmitoyl-oleoyl-phosphatidyl-choline lipids.

Molecular dynamics simulations

Three independent simulations starting from different initial velocities were performed for ETAR-ET1 and ETAR-ET3. All the molecular dynamics simulations were performed using the AMBER16 simulation package (21). The simulation protocol is similar to our previous study (22). In brief, each system was first minimized using the steepest descent and conjugate gradient methods. After that, the whole system was gradually heated from 0 to 300 K under NVT (constant volume and temperature) conditions with the restraints of ETAR and two ETs. Then the harmonic restraints were gradually switched off during the simulation in a stepwise manner. Finally, 1,000 ns production simulations were performed under NTP (constant temperature and pressure) conditions. The time step of the simulations was 2 fs and the trajectories were collected every 1 ps.

Data analyses

Simulation data analyses were mainly performed using the CPPTRAJ program of AMBER16 (21). The equilibration of the simulations was assessed by calculating the root mean-square deviations (RMSDs) for the Cα atoms of ETAR and the two ETs. The α-helix secondary structures of ETAR and the two ETs were evaluated using the DSSP method (23). The α-helix occupancy for each residue was calculated by the percentage of time that the residue existed in the α-helix during the equilibrated simulations. The dynamical flexibilities of ETAR and the two ETs were assessed by computing root mean-square fluctuation (RMSF) on a residue-by-residue basis and then averaged over the equilibrated simulations. The volumes for the orthosteric pocket of ETAR were calculated by POVME 2.0 (24).

The binding free energies between ETAR and the two ETs were calculated using the molecular mechanics/generalized Born surface area approach (25). The calculation procedure is similar to our previous study (22). In brief, the binding free energy (ΔGbinding) was computed by summing the molecular mechanics energy including the electrostatic energy (ΔEelec) and the van der Waals energy (ΔEvdw), the solvation free energy including a polar part (ΔGpol), and a nonpolar part (ΔGnonpol), and the entropy contribution to the binding (-TΔS). The entropy calculations were performed using normal mode analysis in AMBER16. In the calculations, the distance-dependent dielectric constant was set to 4.0, and the energy gradient of minimization was 0.001 with 10,000 minimization cycles per frame. For each simulation, 1,000 frames were evenly extracted from the trajectory to obtain the time-dependent binding free energy. To compare the binding free energies between ETAR-ET1 and ETAR-ET3, the energy data from the last 400 ns were used for analysis. The data from the three independent simulations were averaged to get the mean values and the standard errors. To determine which residues of ETAR and the two ETs play important roles in the binding, the interaction energy was calculated by decomposing the binding free energy based on each residue of the receptor and the two ETs.

For comparison, the mean values and standard errors for the binding free energy, pocket volume, and distance between TM1 and TM6 on the intracellular side were calculated from the three independent simulations. Based on the trajectory equilibration analysis, only the last 400 ns simulation data were used to compare the average data between ETAR-ET1 and ETAR-ET3. Significant differences for the studied variables were determined using Student's t-test (26) with 95% confidence. To compare the binding modes of ET1 and ET3 in ETAR, the representative structures for ETAR-ET1 and ETAR-ET3 were obtained by clustering analysis using the MMTSB toolset (27). PDB structures for ETAR-ET1 and ETAR-ET3 were generated from the last 400 ns molecular dynamics trajectories with a 100 ps interval. A centroid structure was obtained by averaging the PDB structures. Clustering analysis was performed using the K-means algorithm (28) based on the RMSD similarity of the structures. The structure that has the lowest RMSD from the centroid structure was obtained as the representative structure. Visual molecular dynamics (29) was used for the visualization of the structures.

Results and discussion

In this study, the structures of ETAR in complex with ET1 and ET3 were modeled based on the crystal structure of ETBR in complex with ET1 using homology modeling. Homology modeling is a powerful tool to predict an unknown protein structure based on a structure of a homologous protein (30). Over the modeled region, the sequence of ETAR (amino acids 67–384) has nearly 67% identity with that of ETBR (amino acids 88–401). This is much higher than the 30% sequence identity that is considered reliable to model membrane proteins (31,32).

Totally, three independent molecular dynamics simulations were performed for the system of ETAR in complex with ET1 (ETAR-ET1) and that of ETAR in complex with ET3 (ETAR-ET3). Before data analyses, the RMSDs for the Cα atoms of ETAR and the two ETs were calculated to evaluate the equilibrations of the simulations (Fig. 1 B). The RMSD values of ETAR and the two ETs got equilibrated after 600 ns in all the simulations, thus the last 400 ns simulation trajectories were used to obtain average values and standard errors for the studied variables.

The RMSD values of ETAR are around 4–5 Å (black lines in Fig. 1 B). These large structural deviations mainly resulted from the structural flexibility of the loop regions of ETAR, and the RMSD values only reached around 2 Å when the loop regions of the receptor were excluded in the RMSD calculations (Fig. S2). To investigate the detailed structural deviation of ETAR, the RMSD values for each helix of the receptor were calculated (Fig. S3). Most helices kept stable structures with the RMSD values smaller than 2 Å. However, the RMSD values of TM6 and TM7 were larger than other helices and reached around 3 Å at the end of most simulations. This indicates that TM6 and TM7 underwent large conformational changes during the simulations. Compared with those of ETAR, the RMSD values of ETs are smaller (red lines in Fig. 1 B). Representative structures show that ET1 and ET3 share a similar binding mode with ETAR, especially for the helical and C-terminal regions of ETs (Fig. 1 C). The RMSD difference between ET1 and ET3 is 1.09 Å, with large structural deviations in the N-terminal region of ETs. The detailed analyses for the interactions between ETs and ETAR will discuss later in this study.

ET1 has greater binding free energy with ETAR than ET3

Experimental data indicate that the binding affinity of ETAR with ET1 is much higher than that with ET3 (11). To test whether it is the case in the simulations, binding free energies between ETAR and the two ETs were calculated (Table 1 and Fig. S4). In addition, the components of binding free energy were computed to analyze which component plays an important role in the binding (Table 1). For the binding free energies, a negative value means the energy is favorable for the binding, whereas a positive value means the energy is unfavorable for the binding.

Table 1.

Comparison of the binding free energies (kcal/mol) between ETAR-ET1 and ETAR-ET3

Energy ETAR-ET1 ETAR-ET3
ΔEelec −625.47 ± 2.26 −478.03 ± 2.38
ΔEvdw −140.68 ± 0.44 −121.21 ± 0.47
ΔGpol 697.17 ± 2.05 535.89 ± 2.29
ΔGnonpol −21.97 ± 0.05 −20.00 ± 0.05
–TΔS 51.32 ± 0.80 51.17 ± 0.80
ΔGelec+pol 71.70 ± 3.05 57.86 ± 3.30
ΔGvdw+nonpol −162.65 ± 0.44 −141.21 ± 0.47
ΔGbinding −39.63 ± 1.16 −32.18 ± 1.04

ET1 has greater binding free energy with ETAR than ET3. ΔEelec, electrostatic energy in the gas phase; ΔEvdw, van der Waals energy; ΔGpol, polar solvation energy; ΔGnonpol, nonpolar solvation energy; ΔGbinding = ΔEele + ΔEvdw + ΔGpol + ΔGnonpolTΔS. Indicates that the difference is significant.

Among the energy components, the electrostatic energy (ΔEelec), van der Waals energy (ΔEvdw), and nonpolar solvation energy (ΔGnonpol) are favorable for binding, whereas the polar solvation energy (ΔGpol) and entropy contribution (–TΔS) are unfavorable for binding. The entropy contribution is the same between the two systems (51.32 ± 0.80 kcal/mol in ETAR-ET1 vs. 51.17 ± 0.80 kcal/mol in ETAR-ET3), thus it does not contribute to the difference of the binding. The effect of electrostatic energy (ΔEelec) is counteracted by that of polar solvation energy (ΔGpol), and the sum of the two polar energy contributions (ΔGelec+pol) is unfavorable for the binding. In contrast, the sum of the two nonpolar energy contributions (ΔGvdw+nonpol) shows that the nonpolar and van der Waals interactions contribute favorably to the binding. By summing all the components, the binding free energy (ΔGbinding) of ETAR-ET1 (−39.63 ± 1.16 kcal/mol) is much greater than that of ETAR-ET3 (−32.18 ± 1.04 kcal/mol). To validate the simulation results, the binding affinities between ETAR and ETs were also calculated using the PRODIGY web server (33). PRODIGY is a contact-based binding affinity predictor that uses structural properties of protein-protein interactions, the number of interfacial contacts, and noninteracting surfaces to predict the binding affinity between proteins (34). Results show that the binding affinity is −11.18 ± 0.98 kcal/mol for ETAR-ET1, whereas it is −9.68 ± 0.80 kcal/mol for ETAR-ET3. Thus, our simulation results are consistent with the experimental data that ETAR has a higher binding affinity with ET1 than that with ET3.

The binding affinities of ET1 and ET3 for ETAR and ETBR have been studied by TGF-α shedding and β-arrestin recruitment assays (14). To further investigate whether our simulation results are consistent with the data of the two assays, two additional simulations for systems of ETBR with ET1 and ET3 (denoted as ETBR-ET1 and ETBR-ET3) were carried out. Then, molecular mechanics/generalized Born surface area calculations were performed for the two systems and the results are presented in Fig. S5 and Table S1. The binding free energy for ETBR-ET1 (−37.41 ± 1.97 kcal/mol) is similar to that for ETBR-ET3 (−37.96 ± 2.18 kcal/mol). Furthermore, the binding free energy for ETAR-ET3 (−32.18 ± 1.04 kcal/mol) is much smaller than that for ETAR-ET1 (−39.63 ± 1.16 kcal/mol), ETBR-ET1 (−37.41 ± 1.97 kcal/mol), and ETBR-ET3 (−37.96 ± 2.18 kcal/mol). Therefore, the simulation results are consistent with the data of TGF-α shedding and β-arrestin recruitment assays that ET1 binds ETAR and ETBR with similar affinities, while ET3 binds ETAR with a much lower affinity. Since we focus on the selectivity of ETAR with ET1 and ET3 in this study, we do not further discuss the interaction details of ETBR with ET1 and ET3.

Residues of ETAR that show different preferences in the binding of ET1 and ET3 are identified

To investigate which residues of ETAR play important roles in the binding with ET1 and ET3, the interaction energy for each residue of ETAR was calculated by decomposing the binding free energy (upper panel in Fig. 2 A). Interaction energy results indicate that residues R145ECL1, W146ECL1, F1613.28, P1623.29, K1663.33, V1693.36, F224ECL2, V227ECL2, F229ECL2, Y231ECL2, T238ECL2, M240ECL2, K2555.38, L2595.42, Y2635.46, W3196.48, L3226.51, R3266.55, R3407.24, and I3557.39 of ETAR contribute positively to the binding of ETAR with both ET1 and ET3; whereas residues D1332.57, K1402.64, E2204.60, E234ECL2, D2565.39, K3296.58, E335ECL3, and D3517.35 are unfavorable for the binding. (The superscript after each residue indicates Ballesteros-Weinstein numbering for the residues of GPCRs (35).) All the residues unfavorable for binding are charged residues, thus these residues may affect the binding through long-range electrostatic interactions. In addition to the residues that are favorable for the binding of ETAR with the two ETs, several residues only favor the binding with one of the ETs: residues Y68N-ter, L3447.28, L3487.32, and Y3527.36 are favorable for the binding of ETAR with ET1, whereas residues F148ECL1, Q1653.32, L241ECL2, N242ECL2, and A243ECL2 are favorable for the binding of ETAR with ET3.

Figure 2.

Figure 2

Identification of residues preferable for the binding of ETAR with ET1 or ET3. (A) Upper panel: interaction energy for each residue of ETAR in ETAR-ET1 (black) and ETAR-ET3 (red). Residues responsible for the binding of both ET1 and ET3 are labeled in blue, residues that favor ET1 are labeled in gray, residues that favor ET3 are labeled in purple, and residues that disfavor the binding are labeled in orange. Lower panel: difference of the interaction energy (green) between ETAR-ET1 and ETAR-ET3. Residues that favor ET1 are labeled in black, whereas residues that favor ET3 are labeled in red. Residues labeled in orange are those that disfavor the binding of both ET1 and ET3 in the upper panel. The regions for the transmembrane helices are shaded in gray. (B) Upper panel: interaction energy for each residue of ET1 and ET3. Lower panel: difference of the interaction energy between ET1 and ET3. The regions for the three regions of ET1/3 are shaded in blue, orange, and purple, respectively. The concentric circles show the positions of cysteine residues that form two intramolecular disulfide bonds. The residues that favor ET1 and ET3 binding to ETAR are labeled using black and red dotted lines, respectively. To see this figure in color, go online.

Among the residues that are favorable for the binding of ETAR with both ET1 and ET3, several of them display different preferences in the binding with the two ETs. To further study how these residues discriminate ET1 and ET3, the interaction energy difference between each residue of ETAR in ETAR-ET1 and ETAR-ET3 was calculated (lower panel in Fig. 2 A). In the results of interaction energy difference, a residue with a negative value is preferred for the binding with ET1, whereas a residue with a positive value is preferred for the binding with ET3. It reveals that besides the four residues (i.e., Y68N-ter, L3447.28, L3487.32, and Y3527.36), residues R145ECL1, F229ECL2, Y231ECL1, R232ECL2, H236ECL2, L2595.42, W3196.48, L3226.51, R3266.55, K3296.58, M336ECL3, and R3407.24 are preferred for the binding with ET1; while in addition to the five residues (i.e., F148ECL1, Q1653.32, L241ECL2, N242ECL2, and A243ECL2), residues F1613.28, K1663.33, F224ECL2, Q2525.35, and K2555.38 are preferred for the binding with ET3.

Recently, the interaction features of GPCRs with peptide ligands have been studied based on the knowledge of GPCR-peptide structures and mutagenesis data (36). The study reveals that the residues at positions 3.29, 3.32, 3.33, 4.60, 4.64, 5.42, and 6.55 in GPCRs are highly conserved between the members of GPCRs and these residues are vital for the binding of peptide ligands (36). Consistent with the study, our interaction energy analysis demonstrates that these residues of ETAR are essential for the binding of ET1 and ET3 (Fig. 2 A).

To further test whether the interaction residues identified in our simulations are in line with experimental data, the mutagenesis data that analyze the interactions of ETAR with ETs and antagonists were obtained from the GPCRdb database (37) and summarized in Table S2. Among the mutations, Q165D3.32 and K140I2.64 reduce the binding affinity of ETAR with ET1. This is consistent with our interaction energy analysis that Q165 and K140 play important roles in the binding of ET1 and ET3 (Fig. 2 A). Of the mutations, L142M2.66, A143K2.67, G144MECL1, F156I3.23, S167A3.34, T172V3.39, E220N4.60, V225A/DECL2, G261A5.44, F264L5.47, F320A6.49, H323F6.52, K330I6.59, and N361A7.45 show no significant change in the binding of ET1. This is in agreement with our simulation results that the residues corresponding to the mutations are not involved in the binding of ETs (Fig. 2 A). Furthermore, the mutagenesis data show that the mutations including D126A2.50, Y129F/W/K/S/A2.53, D133N/A2.57, K159Q3.26, F260Y5.43, Y263F5.46, F315L6.44, R326Q6.55, and D351N7.35 reduce the binding affinity of ET receptor antagonists (bosentan or BMS-182874) rather than that of ETs (Table S2). As the residues corresponding to these mutations do not affect the binding of ETs (Fig. 2 A), these residues may be used to differentiate the binding of ETs and antagonists.

To date, three nonpeptide ET receptor antagonists have been approved, i.e., bosentan, ambrisentan, and macitentan (38). While ambrisentan is an ETAR-selective antagonist, bosentan and macitentan are nonselective antagonists that block both ETAR and ETBR. The crystal structure of ETBR in complex with bosentan shows that K1823.33, K2735.38, and R3436.55 of ETBR are critical for the binding of bosentan (39). Computational study identifies that the corresponding residues in ETAR (i.e., K1663.33, K2555.38, and R3266.55) play important roles in the binding of bosentan and the potential natural inhibitors of ETAR (40). Similar to the binding of the antagonists, our simulation results also indicate that the three residues are vital in the binding of ET1 and ET3 (Fig. 2 A).

Recent mutagenesis data demonstrate that residues L3226.51, R3266.55, and I3557.39 of ETAR showed pronounced and differential effects on the binding of the three approved antagonists (41): 1) the mutation L322A6.51 reduces the antagonist activity of macitentan, whereas bosentan and ambrisentan are unaffected; 2) the mutation R326Q6.55 does not affect the antagonist activity of macitentan, but reduces the activity of bosentan and ambrisentan; and 3) the mutation I355A7.39 significantly reduced bosentan potency, but not ambrisentan and macitentan potencies. It is noted that L3226.51 and R3266.55 in our simulations are preferable for the binding of ET1, while I3557.39 contributes equally to the binding of ET1 and ET3 (Fig. 2 A). These findings that residues L3226.51, R3266.55, and I3557.39 differentiate the binding of ETs and the antagonists may help to design novel ETAR inhibitors.

ETAR discriminates ET1 and ET3 by the residue at position 14 of the two ETs

A comparison of the sequence between ET1 and ET3 shows that six residues (five in the N-terminal region and one in the α-helical region) are different between ET1 and ET3, while most of the residues in the α-helical and C-terminal regions are conserved between the two ETs (Fig. 1 A). To investigate which residues of ET1 and ET3 contribute positively to the binding of ETAR, the interaction energy for each residue of ETs was calculated (upper panel in Fig. 2 B). Since the four cysteine residues of ETs form two intramolecular disulfide bonds (i.e., C1-C15 and C3-C11) that are mainly responsible for the structural stability of the two ETs, the effects of these four residues on the binding are not further discussed. Results show that residues D8, V12, Y13, residue 14 (F14 in ET1 and Y14 in ET3), H16, and L17 in the α-helical region and the four residues (18DIIW21) in the C-terminal region have large interaction energies, indicating that these residues play essential roles in the binding with ETAR.

Although the residues in the N-terminal region play a less important role in the binding, the difference between these residues in ET1 and ET3 may affect the ligand selectivity of ETAR. To evaluate which residues in ET1 and ET3 are responsible for the selectivity of ETAR, the interaction energy difference for the two ETs was calculated (lower panel in Fig. 2 B). For the interaction energy difference, a negative value indicates that the residue is preferred for the binding of ET1 with ETAR, whereas a positive value indicates that the residue is preferred for the binding of ET3 with ETAR. Results reveal that residues S5, M7, D8, F14, and W21 in ET1 are preferred for the binding with ETAR compared with the corresponding residues in ET3; while residues T2, F4, Y13, and I20 in ET3 are preferred for the binding with ETAR compared with the corresponding residues in ET1.

It is noted that, among the six residues that are different between ET1 and ET3, the residue at position 14 (F14 in ET1 and Y14 in ET3) is a key residue that plays an important role in the binding between ETAR and ETs (upper panel in Fig. 2 B). Moreover, compared with the other residues, this residue has the largest value for the interaction energy difference (lower panel in Fig. 2 B), demonstrating that F14 in ET1 is more preferable for the binding with ETAR than Y14 in ET3. Thus, these data suggest that the residue at position 14 plays an important role in discriminating the selectivity of ETAR with ET1 and ET3.

ETAR reveals different interaction patterns with ET1 and ET3

The residues of ETAR that discriminate ET1 and ET3 have been identified in this work (Fig. 2). To give a clear view of how these residues interact with the two ETs, the representative simulation structures showing the detailed interaction for each residue of ETs are presented in Figs. 3 and S6. The interactions for residues in positions 1, 3, 11, and 15 of ETs are not discussed since these four residues form two intramolecular disulfide bonds that are mainly responsible for the structural stability of the two ETs. By comparing the interactions between each residue of ET1 and that of ET3, the reasons why the residues of ET1 and ET3 are more preferable for the binding with ETAR are discussed.

Figure 3.

Figure 3

Comparison of the interactions of ETAR with ET1 and ET3. (A) Comparison of the interactions of ETAR with the residues in the N-terminal region of the two ETs. Compared with S2 and S4 of ET1, T2 and F4 of ET3 have more interactions with ETAR. (B) Comparison of the interactions of ETAR with the residue at position 14 of the two ETs. Dotted circles indicate that there are hydrophobic contacts between the residues in the circle. There are large numbers of hydrophobic contacts between F14 of ET1 and residues Y68, L344, and L348 of ETAR; however, there are few contacts between Y14 of ET3 and the three residues of ETAR. (C) Comparison of the interactions of ETAR with I20 of the two ETs. Both F161 of ETAR and I20 of ET3 undergo orientation changes, which allows F161 to move closer to I20 of ET3. (D) Comparison of the interactions of ETAR with W21 of the two ETs. Compared with that in ET1, W3196.48 in ET3 undergoes an orientation change. The green dotted lines indicate that there is a hydrogen bond between the two residues. The carbon atoms in residues of ETAR are shown in tan, while the carbon atoms in residues of the N-terminal, α-helical, and C-terminal regions of the two ETs are shown in cyan, orange, and purple, respectively. The nitrogen atoms are shown in blue, oxygen atoms in red, and hydrogen atoms in white. For clarity, only the side chain of each residue is shown. To see this figure in color, go online.

The interactions of residues in the N-terminal region of ETs are shown in Fig. 3 A, which reveals that residue S2 and L6 of ET1 are surrounded by M240ECL2, L241ECL2, Q2525.35, N242ECL2, V225ECL2, and V227ECL2 of ETAR; whereas T2 and Y6 of ET3 are surrounded by the same residues except that the interacting residues N242ECL2 and V255ECL2 in ETAR-ET1 are replaced by A243ECL2 and T244ECL2 in ETAR-ET3. In ET1, there is no interaction for residues S4, S5, and M7. Similarly, no interaction is found for T5 and K7 in ET3. However, residue F4 in ET3 interacts with E355ECL3 and M336ECL3 of ETAR. In addition, the side chain of T2 in ET3 forms a hydrogen bond with the main chain oxygen atom of Q2525.35. Due to these interactions, T2 and F4 in ET3 are more preferable for the binding with ETAR than S2 and S4 in ET1 (lower panel in Fig. 2 B).

The interactions for residues in the α-helical region of ETs are shown in Figs. 3 B and S6, which reveals that residues D8, K9, E10, V12, and Y13 in the two ETs have similar interactions with ETAR (Fig. S6 A). These residues in ET1 are surrounded by Y68N-ter, F227ECL2, F229ECL2, Y231ECL2, H236ECL2, T238ECL2, M240ECL2, and R3407.24 of ETAR. Similarly, these residues in ET3 are surrounded by the same residues of ETAR except that the interacting residue F277ECL2 in ETAR-ET1 is replaced by R145ECL1 in ETAR-ET3. Compared with that in ET1, residue Y13 in ET3 forms a cation-π interaction with R145ECL1. The strong interaction formed by these two residues in ETAR-ET3 may explain why Y13 is more preferable for the binding of ETAR with ET3 (Fig. 2 B).

The comparison of the interactions between F14 in ET1 and Y14 in ET3 is displayed in Fig. 3 B, which reveals that F14 of ET1 is located in a hydrophobic environment formed by Y68N-ter, L3447.28, and L3487.32 of ETAR. However, Y14 of ET3 brings in a hydrophilic hydroxyl group that would impede the hydrophobic interactions with the three residues of ETAR. To confirm whether this is the case, the hydrophobic contacts between F/Y14 of the two ETs and the three residues of ETAR were calculated (Fig. S7). According to the work of Cheng et al. (42), a contact was counted if any two carbon atoms between the two residues were identified within 5.4 Å. Results show that there are large numbers of hydrophobic contacts between F14 of ET1 and the three residues of ETAR; however, there are few or even no contact between Y14 of ET3 and the three residues of ETAR (Fig. S7). Combining the interaction energy data that Y68N-ter, L3447.28, and L3487.32 of ETAR are favorable for the binding with ET1 but not ET3 (Fig. 2 A), these results demonstrate that ETAR discriminates ET1 and ET3 by using the three residues Y68N-ter, L3447.28, and L3487.32 to recognize the residue at position 14 of the two ETs.

In both ET1 and ET3, residues H16 and L17 in the α-helical region are surrounded by five residues of ETAR, i.e., K1402.64, R145ECL1, W146ECL1, H236ECL2, and T238ECL2 (Fig. S6 B). However, in ET1, another three residues of ETAR (i.e., Y68N-ter, L3487.32, and Y3527.36) have contacts with L17; whereas in ET3, residue T73N-ter of ETAR is also involved in the interaction with L17. Residues D18 and D19 in the C-terminal region are surrounded by five residues of ETAR, i.e., K1402.64, L3226.51, R3266.55, D3517.35, and I3557.39 (Fig. S6 C). However, in ET1, another three residues of ETAR (i.e., L1412.65, L3487.32, and Y3527.36) have contacts with D18; whereas in ET3, residues D1332.57 and Q1653.32 of ETAR are also involved in the interaction with I19. The interaction energy differences for residues H16, L17, D18, and I19 are small between ET1 and ET3 (Fig. 2 B), thus these residues are less important for the ligand selectivity.

The interaction comparison for I20 in ET1 and ET3 is presented in Fig. 3 C, which shows that I20 in both ET1 and ET3 is surrounded by F1613.28, P1623.29, Q1655.32, and F224ECL2 of ETAR. However, compared with that in ET1, I20 in ET3 undergoes an orientation change. This change is examined by calculating the dihedral angle for the side chain of I20. The dihedral angle is distributed around 65° in ET1, but it is also distributed around 207 and 300° in ET3 (Fig. S8 A). Accompanied with this change, F1613.28 also undergoes an orientation change. The dihedral angle for the side chain of F1613.28 is changed from ∼275° in ET1 to ∼190° in ET3 (Fig. S8 B), which allows F1613.28 to move closer to I20 of ET3. Combining with the result that F1613.28 is favorable for the interaction with ET3 (Fig. 2 B), the closed interaction between F1613.28 of ETAR and I20 of ET3 makes I20 preferable for the binding of ETAR with ET3 but not ET1.

The interaction energy results have demonstrated that the C-terminal W21 in both ET1 and ET3 plays an essential role in the binding with ETAR (upper panel in Fig. 2 B). In both ETAR-ET1 and ETAR-ET3, W21 penetrates into the bottom of the orthosteric pocket and interacts with eight residues of ETAR, i.e., Q1653.32, K1663.33, V1693.36, L2595.42, Y2635.46, W3196.48, H3236.52, and R3266.55 (Fig. 3 D). Taken together, these residues contribute greatly to the binding between ETAR and the two ETs. Besides the eight residues, W21 in ET1 is also surrounded by E2204.60, K2555.38, and L3226.51, whereas W21 in ET3 is also surrounded by D2565.39. Notably, the orientation of W3196.48 in ETAR-ET3 is different from that in ETAR-ET1, which may make the residue W3196.48 less favorable for the binding of ET3. The residue W3196.48 is located in the CWxP motif that is reported to be involved in the signaling function of GPCRs (43). The effect of how the orientation change alters the signaling function of ETAR is discussed in the following section.

ET1 has higher structural and dynamical stabilities in binding with ETAR

To study whether there are structural differences of ETAR in the binding of ET1 and ET3, secondary structure analysis for ETAR was performed (Fig. 4 A). A comparison of the occupancies for all the helices of ETAR reveals that the occupancies for TM2, TM3, TM4, and TM5 are similar between ETAR-ET1 and ETAR-ET3 (Table S3). In contrast, the occupancies for TM1, TM6, and helix 8 in ETAR-ET1 are smaller than those in ETAR-ET3, whereas the occupancy for TM7 in ETAR-ET1 is larger than that in ETAR-ET3 (Table S3). By summing the occupancies for all the residues, the total helix occupancy of ETAR in ETAR-ET1 is similar to that in ETAR-ET3 (63.8 vs. 64.3%). The secondary structure analysis was also performed for the α-helical region of ET1 and ET3 (Fig. 4 B). Results indicate that the occupancy for the α-helical region of ET1 is larger than that of ET3 (59.3 vs. 56.7%). Furthermore, the occupancy for F14 of ET1 is much larger than that for Y14 of ET3 (97.8 vs. 81.1%). From a structural point of view, this result supports the data that F14 of ET1 is more preferable for the binding of ETAR than Y14 of ET3.

Figure 4.

Figure 4

Comparison of the secondary structure between ETAR-ET1 and ETAR-ET3. (A) Comparison of the helix occupancy of ETAR in ETAR-ET1 with that in ETAR-ET3. The total helix occupancy for ETAR is similar between the two systems. (B) Comparison of the helix occupancy for each residue in the α-helical region of ET1 and ET3. The total helix occupancy for the α-helical region of ET1 is larger than that of ET3, indicating that ET1 is structurally more stable in the binding with ETAR. To see this figure in color, go online.

The RMSF for each residue of ETAR and the two ETs was calculated to assess whether there are dynamical differences between ETAR-ET1 and ETAR-ET3 (Fig. 5). For ETAR, the RMSF values for the loop regions and helix 8 are large; whereas the values for TM1-7 are small (<1 Å) in both ETAR-ET1 and ETAR-ET3 (Fig. 5 A). However, the RMSF values for TM2-7 in ETAR-ET1 are smaller than those in ETAR-ET3, indicating that these transmembrane helices of ETAR are dynamically stable in the binding of ET1. For the two ETs, the RMSF values for the residues in the α-helical region are similar between ETAR-ET1 and ETAR-ET3 (Fig. 5 B). However, the RMSF values for the residues in the N-terminal and C-terminal regions of ET1 are smaller than those of ET3, indicating that ET1 is dynamically more stable in the binding with ETAR than ET3.

Figure 5.

Figure 5

Comparison of the dynamic flexibility between ETAR-ET1 and ETAR-ET3. (A) Comparison of the RMSF value for each residue of ETAR in ETAR-ET1 with that in ETAR-ET3. The RMSF values for TM2-7 in ETAR-ET1 are smaller than those in ETAR-ET3. (B) Comparison of the RMSF values for each residue of ET1 and ET3. The RMSF values for the residues in the N-terminal and C-terminal regions of ET1 are smaller than those of ET3, indicating that ET1 is dynamically more stable in the binding with ETAR. To see this figure in color, go online.

Conformational difference of ETAR in the binding of ET1 and ET3 is identified

We have found that, compared with that in ETAR-ET1, W3196.48 in ETAR-ET3 undergoes an orientation change (Fig. 3 D). This change results in a vertical conformation of the side chain of W3196.48 with respect to the side chain of W21, which leads to a less tight packing of W3196.48 with W21 of ET3 (Fig. 3 D). This observation is consistent with the interaction energy analysis that the interaction energy value of W3196.48 in ETAR-ET3 is smaller than that in ETAR-ET1 (−0.49 kcal/mol in ETAR-ET1 vs. −0.27 kcal/mol in ETAR-ET3 in the upper panel of Fig. 2 A). In both ETAR-ET1 and ETAR-ET3, the contribution of W3196.48 to the interaction energy is small, thus it is less likely that W3196.48 determines the binding affinities of ETAR with ETs. However, since this residue is located in the CWxP motif that plays an important role in regulating the signaling function of GPCRs, the orientation change of W3196.48 caused by the binding of ET3 may lead to the conformational rearrangement of ETAR. This proposition is supported by the findings that, when ET1 or ET3 binds to ETBR, W3366.48 in ETBR (residue corresponding to W3196.48 in ETAR) moves downward and induces a conformational change of its neighboring residue F3326.44 (residue corresponding to F3156.44 in ETAR) in the middle part of TM6, which may ultimately result in an outward displacement of TM6 in the intracellular side of ETBR (13,14).

To investigate whether the orientation change of W3196.48 can affect the interactions with its neighboring residues, the representative structures showing the interactions of W3196.48 in ETAR-ET1 and ETAR-ET3 are presented (Fig. 6 A). This shows that W3196.48 is surrounded by four residues Y1292.53, F3156.44, I3557.39, and N3617.45 in ETAR-ET1; however, due to the rotation of Y1292.53, W3196.48 lost its interaction with Y1292.53 in ETAR-ET3. To check whether the neighboring residues also undergo orientation changes, the dihedral angles for the side chain of W3196.48 and its neighboring residues were computed (Figs. 6 B and S9). Results reveal that, besides W3196.48, the neighboring residues Y1292.53, F3156.44, and I3557.39 also undergo orientation changes. Since W3196.48 is located in the CWxP motif that plays an important role in the signaling function of GPCRs, the changes of this residue and its neighboring residues may cause the conformational change of ETAR.

Figure 6.

Figure 6

Orientation changes of W319 and its neighboring residues. (A) Comparison of the interactions of W319 with its neighboring residues Y129, F315, and I355. W319 undergoes orientation change and loses its contact with Y129 in ETAR-ET3. (B) The distributions for the dihedral angle of the side chain of W319 and its neighboring residues. Accompanied with W319, residues F315, I355, and Y129 also undergo orientation changes. To see this figure in color, go online.

Similar to the role of W3666.48 in regulating the conformation of ETBR, the orientation changes of W3196.48 and its neighboring residues may also cause the conformational change of ETAR. The conformational change of ETAR is first explored by calculating the volume of the orthosteric pocket for the binding of ET1 and ET3 (Figs. 7 and S10). The averaged pocket volume is 1701.02 ± 10.00 Å3 in ETAR-ET1, but is 1932 ± 8.68 Å3 in ETAR-ET3. Compared with that for ET1, the pocket volume for ET3 is significantly increased. A comparison of the final structures of ETAR in ETAR-ET1 and ETAR-ET3 shows that the volume expansion for the orthosteric pocket of ETAR in ETAR-ET3 comes from the rearrangements of TM2, TM6, and TM7 on the extracellular side, which may result in the unstable binding of ETAR with ET3.

Figure 7.

Figure 7

Conformational difference of ETAR in binding of ET1 and ET3. Figures are shown from side and extracellular views. Compared with ET1, the orthosteric pocket volume for ET3 is significantly increased. The volume expansion for the orthosteric pocket of ETAR in ETAR-ET3 results from the rearrangements of TM2, TM6, and TM7 on the extracellular side. Compared with that in ETAR-ET1, TM6 in ETAR-ET3 also undergoes conformational change on the intracellular side. To see this figure in color, go online.

The conformational change in the orthosteric pocket of ETAR may subsequently lead to the intracellular conformational change of ETAR. To test this proposition, the distance between R1031.55 and K1996.28, which represents the distance between the intracellular ends of TM1 and TM6, was calculated (Figs. 7 and S11). Results show that the distance is 33.53 ± 0.05 Å in ETAR-ET1, but it is 31.57 ± 0.07 Å in ETAR-ET3. Compared with that in ETAR-ET1, the distance in ETAR-ET3 is significantly decreased. This indicates that the intracellular conformations of ETAR are different between ETAR-ET1 and ETAR-ET3. Recently, a simulation study demonstrated that angiotensin type 1 receptor, a prototypical GPCR, adopts two active intracellular conformations when binding with angiotensin II and its peptide analogs (44). One of the conformations couples to both G-proteins and β-arrestins, whereas the other only couples to β-arrestins and shows more inactive-like positions of TM6 (44). In this study, a large outward displacement of TM6 that characterizes the activation of GPCRs was not observed in ETAR-ET1 or ETAR-ET3. To further check the activation state of ETAR, the distance between L1222.46 and V3086.37 that is suggested as an indicator for the activation state of ETAR (37) was calculated. The distance is 13.89 ± 0.07 Å in ETAR-ET1 and 12.91 ± 0.13 Å in ETAR-ET3. Thus, despite the conformational differences in the intracellular side of the receptor, ETAR still adopts an inactive state in the simulations. This is consistent with the experimental and simulation findings that the binding of agonists only induces structural heterogeneity of GPCRs, whereas the binding of G-proteins or β-arrestins is necessary to cause the activation conformation of GPCRs (45,46). Similar to angiotensin type 1 receptor, the conformational difference of ETAR in the intracellular side of TM6 caused by the binding of the two ETs may result in preferential signaling to recruit various G-proteins or β-arrestins. To date, the research about the G-protein or β-arrestin biased ETAR signaling is still lacking. Further experimental and theoretical studies are needed to investigate whether the peptide agonists could regulate the biased signaling of ETAR.

Conclusion

In this study, the models of ETAR in complex with the two isopeptides, i.e., ET1 and ET3, were built. Then molecular dynamics simulations were performed for the two models to investigate how ETAR recognizes ET1 and ET3. First, the binding free energy between ETAR and the two ETs was calculated to test which ET is preferable for the binding. Results demonstrate that ET1 has greater binding free energy with ETAR than ET3, which is consistent with the binding affinity data of ETAR. Then the interaction energy for each residue of ETAR and the two ETs was obtained by decomposing the binding free energy. It reveals that residues Y68, R145, F229, Y231, R232, H236, L259, W319, L322, R326, K329, M336, R340, L344, L348, and Y352 of ETAR are preferred for the binding with ET1; while residues F148, F161, Q165, K166, F224, L241, N242, A243, Q252, and K255 of ETAR are preferred for the binding with ET3. Detailed interaction analyses indicate that ETAR can recognize ET1 and ET3 by using residues Y68, L344, and L348 to discriminate F14 of ET1 and Y14 of ET3. Secondary structure and dynamical flexibility analyses show that ET1 is more stable in the binding of ETAR than ET3. In addition, the orientation change of W319 was observed. This residue is located in the conserved CWxP motif that plays an important role in the signaling function of GPCRs. Furthermore, the difference in the orthosteric pocket volume caused by the binding of ET1 and ET3 was found. This difference results from the rearrangement of TM2, TM6, and TM7 on the extracellular side of ETAR. Accompanied with the change in the orthosteric pocket, a conformational difference of TM6 on the intracellular side of ETAR was also observed. All the findings in this study provide a molecular mechanism of how ETAR selects the isopeptides ET1 and ET3, which may help in designing novel ET receptor antagonists to treat cardiovascular and renal diseases.

Author contributions

L.W. and F.Y. conceived the work. L.W. and L.W. carried out all simulations. L.W., L.W., and F.Y. analyzed the data and wrote the manuscript.

Acknowledgments

We thank the Alabama Supercomputer Center and supercomputer facility at the University of Alabama at Birmingham for providing the computational resources. F.Y. acknowledges the National Natural Science Foundation of China (grant no. 21808166) and the Natural Science Foundation of Tianjin (grant no. 18JCYBJC89300) for financial support.

Declaration of interests

The authors declare no competing interests.

Editor: Chris Chipot.

Footnotes

Supporting material can be found online at https://doi.org/10.1016/j.bpj.2022.06.006.

Contributor Information

Lingyun Wang, Email: lywang@uab.edu.

Feng Yan, Email: yanfeng@tiangong.edu.cn.

Supporting material

Document S1. Figures S1–S11 and Tables S1–S3
mmc1.pdf (4.6MB, pdf)
Document S2. Article plus supporting material
mmc2.pdf (7.7MB, pdf)

References

  • 1.Shah R. Endothelins in health and disease. Eur. J. Intern. Med. 2007;18:272–282. doi: 10.1016/j.ejim.2007.04.002. [DOI] [PubMed] [Google Scholar]
  • 2.Barton M., Yanagisawa M. Endothelin: 30 years from discovery to therapy. Hypertension. 2019;74:1232–1265. doi: 10.1161/hypertensionaha.119.12105. [DOI] [PubMed] [Google Scholar]
  • 3.Houde M., Desbiens L., D'Orléans-Juste P. Endothelin-1: biosynthesis, signaling and vasoreactivity. Adv. Pharmacol. 2016;77:143–175. doi: 10.1016/bs.apha.2016.05.002. [DOI] [PubMed] [Google Scholar]
  • 4.Davenport A.P., Hyndman K.A., et al. Maguire J.J. Endothelin. Pharmacol. Rev. 2016;68:357–418. doi: 10.1124/pr.115.011833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Yamamoto E., Awano S., et al. Takehara T. Expression of endothelin-1 in gingival epithelial cells. J. Periodontal. Res. 2003;38:417–421. doi: 10.1034/j.1600-0765.2003.00668.x. [DOI] [PubMed] [Google Scholar]
  • 6.Ling L., Maguire J.J., Davenport A.P. Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer. Br. J. Pharmacol. 2013;168:283–295. doi: 10.1111/j.1476-5381.2011.01786.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Skovsted G.F., Kilic S., Edvinsson L. Endothelin-1 and endothelin-3 regulate endothelin receptor expression in rat coronary arteries. Basic Clin. Pharmacol. Toxicol. 2015;117:297–305. doi: 10.1111/bcpt.12407. [DOI] [PubMed] [Google Scholar]
  • 8.Yokokawa K., Kohno M., et al. Takeda T. Endothelin-3 regulates endothelin-1 production in cultured human endothelial cells. Hypertension. 1991;18:304–315. doi: 10.1161/01.hyp.18.3.304. [DOI] [PubMed] [Google Scholar]
  • 9.Watts S.W. Endothelin receptors: what’s new and what do we need to know? Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010;298:R254–R260. doi: 10.1152/ajpregu.00584.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Aubert J.D., Juillerat-Jeanneret L. Endothelin-receptor antagonists beyond pulmonary arterial hypertension: cancer and fibrosis. J. Med. Chem. 2016;59:8168–8188. doi: 10.1021/acs.jmedchem.5b01781. [DOI] [PubMed] [Google Scholar]
  • 11.Arai H., Hori S., et al. Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  • 12.Sakurai T., Yanagisawa M., et al. Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348:732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  • 13.Shihoya W., Nishizawa T., et al. Doi T. Activation mechanism of endothelin ETB receptor by endothelin-1. Nature. 2016;537:363–368. doi: 10.1038/nature19319. [DOI] [PubMed] [Google Scholar]
  • 14.Shihoya W., Izume T., et al. Nureki O. Crystal structures of human ETB receptor provide mechanistic insight into receptor activation and partial activation. Nat. Commun. 2018;9:4711. doi: 10.1038/s41467-018-07094-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993;234:779–815. doi: 10.1006/jmbi.1993.1626. [DOI] [PubMed] [Google Scholar]
  • 16.Gordon J.C., Myers J.B., et al. Onufriev A. H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005;33:W368–W371. doi: 10.1093/nar/gki464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Studer G., Rempfer C., et al. Schwede T. QMEANDisCo-distance constraints applied on model quality estimation. Bioinformatics. 2020;36:2647. doi: 10.1093/bioinformatics/btaa058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Jo S., Lim J.B., et al. Im W. CHARMM-GUI membrane builder for mixed bilayers and its application to yeast membranes. Biophys. J. 2009;96:41a. doi: 10.1016/j.bpj.2008.12.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hornak V., Abel R., et al. Simmerling C. Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins. 2006;65:712–725. doi: 10.1002/prot.21123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Dickson C.J., Madej B.D., et al. Walker R.C. Lipid14: the Amber lipid force field. J. Chem. Theor. Comput. 2014;10:865–879. doi: 10.1021/ct4010307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Case D.A., Betz R.M., et al. Kollman P.A. University of California; 2016. AMBER 2016. [Google Scholar]
  • 22.Wang L., Yan F. Trans and cis conformations of the antihypertensive drug valsartan respectively lock the inactive and active-like states of angiotensin II type 1 receptor: a molecular dynamics study. J. Chem. Inf. Model. 2018;58:2123–2130. doi: 10.1021/acs.jcim.8b00364. [DOI] [PubMed] [Google Scholar]
  • 23.Kabsch W., Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers. 1983;22:2577–2637. doi: 10.1002/bip.360221211. [DOI] [PubMed] [Google Scholar]
  • 24.Durrant J.D., Votapka L., et al. Amaro R.E. POVME 2.0: an enhanced tool for determining pocket shape and volume characteristics. J. Chem. Theor. Comput. 2014;10:5047–5056. doi: 10.1021/ct500381c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Gohlke H., Kiel C., Case D.A. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J. Mol. Biol. 2003;330:891–913. doi: 10.1016/s0022-2836(03)00610-7. [DOI] [PubMed] [Google Scholar]
  • 26.Bailey N.T.J. Third edition. Cambridge University Press; 1995. Statistical Methods in Biology. [Google Scholar]
  • 27.Feig M., Karanicolas J., Brooks C.L. MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology. J. Mol. Graph. Model. 2004;22:377–395. doi: 10.1016/j.jmgm.2003.12.005. [DOI] [PubMed] [Google Scholar]
  • 28.Hartigan J.A. John Willey & Sons, Inc.; 1975. Clustering Algorithem. [Google Scholar]
  • 29.Humphrey W., Dalke A., Schulten K. VMD: visual molecular dynamics. J. Mol. Graph. 1996;14:33–38. doi: 10.1016/0263-7855(96)00018-5. [DOI] [PubMed] [Google Scholar]
  • 30.Piccoli S., Suku E., et al. Giorgetti A. Genome-wide membrane protein structure prediction. Curr. Genom. 2013;14:324–329. doi: 10.2174/13892029113149990009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Forrest L.R., Tang C.L., Honig B. On the accuracy of homology modeling and sequence alignment methods applied to membrane proteins. Biophys. J. 2006;91:508–517. doi: 10.1529/biophysj.106.082313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Olivella M., Gonzalez A., et al. Deupi X. Relation between sequence and structure in membrane proteins. Bioinformatics. 2013;29:1589–1592. doi: 10.1093/bioinformatics/btt249. [DOI] [PubMed] [Google Scholar]
  • 33.Xue L.C., Rodrigues J.P., et al. Vangone A. PRODIGY: a web server for predicting the binding affinity of protein-protein complexes. Bioinformatics. 2016;32:3676–3678. doi: 10.1093/bioinformatics/btw514. [DOI] [PubMed] [Google Scholar]
  • 34.Vangone A., Bonvin A.M. Contacts-based prediction of binding affinity in protein-protein complexes. Elife. 2015;4:e07454. doi: 10.7554/elife.07454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ballesteros J.A., Weinstein H. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci. 1995;25:366–428. [Google Scholar]
  • 36.Tikhonova I.G., Gigoux V., Fourmy D. Understanding peptide binding in Class A G protein-coupled receptors. Mol. Pharmacol. 2019;96:550–561. doi: 10.1124/mol.119.115915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kooistra A.J., Mordalski S., et al. Gloriam D.E. GPCRdb in 2021: integrating GPCR sequence, structure and function. Nucleic Acids Res. 2021;49:D335–D343. doi: 10.1093/nar/gkaa1080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Enevoldsen F.C., Sahana J., et al. Krüger M. Endothelin receptor antagonists: status quo and future perspectives for targeted therapy. J. Clin. Med. 2020;9:824. doi: 10.3390/jcm9030824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Shihoya W., Nishizawa T., et al. Nureki O. X-ray structures of endothelin ETB receptor bound to clinical antagonist bosentan and its analog. Nat. Struct. Mol. Biol. 2017;24:758–764. doi: 10.1038/nsmb.3450. [DOI] [PubMed] [Google Scholar]
  • 40.Nagarajan H., Vetrivel U. Membrane dynamics simulation and virtual screening reveals potential dual natural inhibitors of endothelin receptors for targeting glaucomatous condition. Life Sci. 2021;269:119082. doi: 10.1016/j.lfs.2021.119082. [DOI] [PubMed] [Google Scholar]
  • 41.Gatfield J., Mueller Grandjean C., et al. Nayler O. Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis. PLoS One. 2014;9:e107809. doi: 10.1371/journal.pone.0107809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Cheng Y., Lindert S., et al. Regnier M. Computational studies of the effect of the S23D/S24D troponin I mutation on cardiac troponin structural dynamics. Biophys. J. 2014;107:1675–1685. doi: 10.1016/j.bpj.2014.08.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Trzaskowski B., Latek D., et al. Filipek S. Action of molecular switches in GPCRs - theoretical and experimental studies. Curr. Med. Chem. 2012;19:1090–1109. doi: 10.2174/092986712799320556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Suomivuori C.M., Latorraca N.R., et al. Dror R.O. Molecular mechanism of biased signaling in a prototypical G protein-coupled receptor. Science. 2020;118:162a. doi: 10.1016/j.bpj.2019.11.1000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Nygaard R., Zou Y., et al. Kobilka B.K. The dynamic process of β2-adrenergic receptor activation. Cell. 2013;152:532–542. doi: 10.1016/j.cell.2013.01.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Sounier R., Mas C., et al. Granier S. Propagation of conformational changes during μ-opioid receptor activation. Nature. 2015;524:375–378. doi: 10.1038/nature14680. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Document S1. Figures S1–S11 and Tables S1–S3
mmc1.pdf (4.6MB, pdf)
Document S2. Article plus supporting material
mmc2.pdf (7.7MB, pdf)

Articles from Biophysical Journal are provided here courtesy of The Biophysical Society

RESOURCES